H eart failure with preserved ejection fraction (HFpEF) is common, accounting for up to half of patients with heart failure (HF), 1,2 and for an increasing proportion of patients hospitalized with acute decompensated HF. 3, 4 Although the pathophysiologic mechanisms underlying HFpEF remain unclear, these patients are more likely to have left ventricular (LV) hypertrophy or concentric remodeling, LV diastolic dysfunction, and left atrial (LA) enlargement. 5 LA size is independently associated with increased risk of morbidity and mortality in HFpEF. 6, 7 Previous studies have demonstrated impairment of LA function in HFpEF, 8-10 with LA reservoir function measured by peak LA strain emerging as a particularly robust measure of LA dysfunction in these patients. 11 However, data on the prognostic relevance of LA dysfunction in HFpEF is limited, 12 and the prognostic value of LA dysfunction beyond measures of LV function is not known.
LA Dysfunction and HFpEF cardiovascular death, HF hospitalization and aborted sudden death, and its individual components.
Methods

Patient Population
The TOPCAT trial was designed to determine the efficacy of the aldosterone antagonist spironolactone to reduce cardiovascular morbidity and mortality in patients with HFpEF. 13 A total of 3445 adults at least 50 years of age with symptomatic HF, a left ventricular ejection fraction (LVEF) ≥45% per local site reading, controlled systolic blood pressure, and a serum potassium level of <5 mmol/L were enrolled. Eligible patients had at least 1 hospitalization in the past 12 months for which HF was a major component or, if no qualifying hospitalization, a B-type natriuretic peptide (BNP) in the past 60 days ≥100 pg/mL or N-terminal pro-BNP ≥360 pg/mL. Baseline demographics and clinical characteristics of the trial population were previously described in detail. 14 For quality control purposes, each enrolling site was required to submit echocardiographic images obtained within 6 months before enrollment from at least the first 2 randomized patients to the echocardiographic core laboratory for verification of LVEF as previously described in detail. 5 At 27 sites, patients consenting to participation in the overall TOPCAT trial were separately consented for participation in the echocardiographic substudy. The current analysis pooled all baseline echocardiograms with quality suitable for quantitative analysis from the echo substudy and the quality assurance studies. All patients provided written informed consent, and the study was approved by the local Institutional Review Board at each site.
Echocardiographic Methods
Standard echocardiographic and Doppler parameters were analyzed using an offline analysis workstation at a dedicated core laboratory blinded to clinical information as previously described. 5 All measurements were made in accordance with the recommendations of the American Society of Echocardiography 15, 16 and included LV and LA dimensions and volumes, right ventricular (RV) areas, LV wall thickness, LV mass, LVEF, RV fractional area change, mitral inflow propagation and mitral annular relaxation velocities, and tricuspid regurgitation jet velocity. LV wall thickness was defined as the average between interventricular septal wall and posterior wall thickness, and relative wall thickness (RWT) was calculated as 2×(posterior wall thickness)/LV end-diastolic diameter. LV hypertrophy (LVH) was defined as LV mass indexed to body surface area >95 g/m 2 in women and >115 g/m 2 in men. Normal geometry was defined as RWT ≤0.42 and no LVH; concentric remodeling as RWT >0.42 and no LVH; concentric hypertrophy as RWT >0. 42 and LVH; and eccentric hypertrophy as RWT ≤0. 42 and LVH.
LA and LV deformation were measured using a B-mode speckletracking vendor-independent software with algorithms designed for the LV (TomTec Imaging Systems, Unterschleissheim, Germany). This software is angle independent and identifies cardiac motion by tracking multiple reference points over time. 17, 18 The LA and LV endocardial borders were traced at the end-diastolic frame of 2-dimensional images acquired from the apical 2-and 4-chamber views. 17 End diastole was defined by the QRS complex or as the frame after mitral valve closure. Speckles were tracked by the software frame by frame during the course of 1 cardiac cycle. Semiquantitative segment tracking was carefully inspected for each image and manually adjusted as needed. For patients in atrial fibrillation (Data Supplement), strain values were averaged over 3 cardiac cycles. 11 For LV deformation, global longitudinal strain (GLS) was calculated as the average LV longitudinal strain across the 12 segments obtained using apical 4-and 2-chamber views as previously described. 19 Because LV myocardial contraction results in ventricular shortening in systole, GLS results in a negative strain value. From LA speckletracking analysis, LA phasic function was measured using volumes and strain indices calculated as the average of the 12 segments obtained using apical 4-and 2-chamber views. LA time-volume curves were generated by calculating LA volume at each phase of the cardiac cycle (LA maximal, LA pre-A, and LA minimum volumes) using the Simpson method. From these LA volumes, LA phasic function was estimated as:
LA emptying fraction (reservoir function)=([LA maximum volume−LA minimal volume]/LA maximum volume)×100
LA passive emptying fraction (conduit function)=([LA maximum volume−LA pre-A volume]/LA maximum volume)×100
LA active emptying fraction (pump function)=([LA pre-A volume−LA minimal volume]/LA pre-A volume]×100
From LA strain analysis, LA reservoir function was estimated using peak strain during ventricular systole (peak LA strain), which represents LA filling during LV systole ( Figure 1 ). Because the LA expands during ventricular systole, peak LA strain is a positive strain value. If >2 segments could not be tracked or there was a lack of a full cardiac cycle, missing view, non-DICOM images, or significant foreshortening of the cavity, the measurements were considered unreliable and the patient was excluded from the analysis. Because Figure 1 . Two-dimensional speckle-tracking imaging in the apical 4-chamber view in a heart failure with preserved ejection fraction patient with impairment of left atrial (LA) function (decreased peak LA strain). dedicated software for LA strain analysis has not yet been released, we used the current software for LV analysis to study the LA strain. Of the 935 studies suitable for conventional echocardiographic measures, images were not in DICOM format in 278 patients and image quality was inadequate in another 191 patients, leaving 466 patients with image quality sufficient for LA speckle tracking. Because atrial fibrillation has been strongly associated with LA dysfunction, 20 the main analysis was performed restricted to patients in sinus rhythm at the time of echocardiography (357 patients; Figure I in the Data Supplement). All LV strain analysis was performed by a single investigator, as was LA strain analysis. Intraobserver variability for peak LA strain was assessed in a sample of 20 randomly selected TOPCAT studies. The coefficient of variation was 7.7% and the intraclass correlation coefficient was 0.96 (95% confidence interval, 0.93-0.99). Reproducibility measures for conventional echocardiographic measures and for the LV strain have been previously published. 5, 19 
Outcomes
The primary outcome for this analysis was the same as for the overall TOPCAT trial, the composite of cardiovascular death, HF hospitalization, and aborted sudden death. HF hospitalization alone and cardiovascular death alone were secondary outcomes. All events were reported by the primary site investigator and independently adjudicated by the Clinical End points Center as previously described. 13
Statistical Analysis
All normally distributed data were presented as mean and SD (continuous data) or as count and proportion (categorical data). To compare patients in the TOPCAT trial not included in this LA strain analysis with patients included ( Table I in the Data Supplement), and to compare patients in the TOPCAT echo study who were included in this analysis with those not included ( Table II in the Data Supplement), we performed χ 2 tests for categorical variables and 2-sided t test with unequal variance for continuous variables. The prevalence of impaired LA deformation was based on thresholds obtained from data in a healthy population with similar age. 11 Smaller numeric values of peak LA strain denote worse LA reservoir function. Values of peak LA strain <26% represented 2 SD below the mean value for this healthy group and were considered abnormal. Analysis was performed for the population overall and stratified by LA size (normal versus enlarged based on the threshold of 34 mL/m 2 ). 16 To assess the association between LA dysfunction and demographics, clinical characteristics, and echocardiographic measures of cardiac structure and function, patients with HFpEF were categorized according to quartiles of peak LA strain with trend tests across ordered groups, using linear regression. Because the available natriuretic peptide levels in TOPCAT were a mixture of BNP and N-terminal pro-BNP, to assess the association of peak LA strain with natriuretic peptide level, we combined these data by calculating the Z score of the log-transformed BNP or N-terminal pro-BNP level for each patient with available data (n=197).
The association of peak LA strain with the outcome variables of interest was assessed using a time to event analysis with univariate and multivariable Cox proportional hazards models, adjusting for prognostic demographic and clinical prognostic covariates (age, sex, race, randomization strata, enrollment region [Americas versus Russia/ Georgia], randomized treatment assignment, history of atrial fibrillation, heart rate, New York Heart Association class, history of stroke, creatinine, and hematocrit) as previously described, 7 as well as LA volume and core laboratory LVEF. The proportional hazards assumption was tested for all analyses, and there was no evidence of violation of the proportional-hazards assumption by LA strain. Similar analyses were performed for LA phasic volumes (reservoir, conduit, and pump function). In addition, we investigated whether prognostic characteristics of the LV in HFpEF, 6, 21 including LVH, LV systolic function measured by GLS, and filling pressure measured by E/E′ ratio, may explain the association of LA functional measures with clinical outcomes because of shared physiological mechanisms. To evaluate if the rhythm at the time of echocardiography may affect the prognostic use of LA strain, we repeated the analysis including all participants with adequate image quality for LA speckle tracking (n=466), including 109 patients in atrial fibrillation at the time of echocardiography. We also tested for effect modification of rhythm at the time of echocardiography on the relationship between LA strain and clinical outcomes. Finally, we performed 2 sensitivity analyses: (1) restricted to patients with normal LA size as LA enlargement has been associated with LA dysfunction 10 and (2) restricted to patients enrolled in the Americas as marked differences in patient characteristics and outcomes were noted by enrollment region in TOPCAT. 22 All statistical analyses were performed with STATA 12.0 (Stata Corp, College Station, TX). All tests were 2-sided and P values of <0.05 were considered statistically significant.
Results
Among the 357 HFpEF patients with measurable peak LA strain, the mean value was 25.9±7.7% and 52% had abnormal peak LA strain based on data in a healthy population with similar age. 11 The LA strain was abnormal in 47% in patients with normal LA size and 71% patients with LA enlargement (Figure 2 ). Compared with the 3088 patients in the TOPCAT trial not included in this LA strain analysis, patients included in this analysis were more frequently female, less frequently white, less frequently enrolled in Russia or Georgia, and less frequently in the previous hospitalization randomization stratum. Diabetes mellitus was more prevalent and, partially by design, a clinical history of atrial fibrillation was less prevalent in the included patients ( Table I in  the Data Supplement) . Similarly, several differences in clinical and echocardiographic measures were noted between patients in the TOPCAT echo study who were included, compared with those not included (n=578) in this analysis ( Table II in the Data  Supplement) , most notably younger age, greater proportion of women and nonwhite patients, lower heart rate and hematocrit, greater LV volumes, higher LVEF, and smaller LA size.
Baseline Correlates of LA Strain
Patients with lower peak LA strain were older and had a higher prevalence of atrial fibrillation when compared with patients with higher peak LA strain (Table 1) . LA strain was not associated with New York Heart Association class. Lower peak LA strain was associated with greater LA size, greater LV and RV systolic dimensions, greater LV mass index, LV wall thickness, and prevalence of hypertrophy ( Table 2 ; Figure II in the Data Supplement). Lower peak LA (Figure 3 ). Worse LA strain was also associated with worse RV systolic function by RVFAC and higher pulmonary artery systolic pressure by the tricuspid regurgitation jet velocity. Among the 197 patients with natriuretic peptide levels measured, worse LA strain was associated with higher natriuretic peptide levels ( Table III in 
Peak LA Strain and Incident Cardiovascular Events
During a median follow-up of 31 (25th and 75th percentile limits 18-43) months, 91 patients (25.5%) experienced the primary composite end point, including 43 (12.0%) cardiovascular deaths and 62 (17.4%) patients with HF hospitalization. Lower peak LA strain was associated with a heightened risk for the primary composite end point (P=0.009) and HF hospitalization alone (P=0.003) in the unadjusted analysis (Table 3 ). This association was independent of demographic and clinical characteristics, LVEF, and LA size for HF hospitalization, but not for the composite outcome. The association of peak LA strain with incident HF hospitalization remained significant after additional adjustment for LVH, but not after further adjustment for LV GLS or E/E′ (Table  4) . Similar results were observed in analysis including patients in atrial fibrillation at the time of echocardiography (Tables IV and V in the Data Supplement). No significant interaction was noted between LA strain and rhythm at the time of echocardiography for the composite end point, cardiovascular death, or HF hospitalization (all P for interaction >0.05). In contrast, these associations were only observed in unadjusted analysis when the analysis was restricted to patients with normal LA size (Table Vi in the Data Supplement). Among patients enrolled in the Americas, peak LA strain remained associated with the primary composite end point and HF hospitalization alone in multivariable analysis adjusting for demographic and clinical characteristics, LVEF, LA size, and LVH, although these associations were not independent of LV GLS and E/E′ (Tables VII and VIII 
LA Phasic Volumes and Incident Cardiovascular Events
Lower LA strain was associated with worse measures of LA conduit and pump function ( Table 1) . Concordant with our findings with peak LA strain, LA emptying fraction-also a measure of LA reservoir function-was associated with a heightened risk for the primary composite end point in unadjusted analysis and for HF hospitalization alone in unadjusted and adjusted analyses (Figure 4 ). Worse LA pump function, measured by the LA active emptying fraction, was also associated with higher risk of the primary composite end point and HF alone, and remained significantly associated with HF hospitalization in adjusted analysis. LA conduit function, reflected in the LA passive emptying fraction, was not prognostic of outcomes.
Discussion
Our study is the largest, to our knowledge, to assess the prognostic implications of LA dysfunction in HFpEF and the Hazard ratios (HRs) are per unit reduction in peak left atrial strain. ACA indicates aborted cardiac arrest; CI, confidence interval; and HF, heart failure. *Adjusted for age, sex, race, randomization strata, enrollment region (Americas versus Russia/Georgia), randomized treatment assignment, history of atrial fibrillation, heart rate, New York Heart Association class, history of stroke, creatinine, hematocrit, left ventricular ejection fraction, left atrial volume index LA Dysfunction and HFpEF first to evaluate the association of LA dysfunction with clinical outcomes beyond clinical predictors and LV features in HFpEF. Worse LA strain was associated with a higher risk of HF hospitalization independent of potential clinical confounders, but not after adjusting for LV systolic deformation and filling pressure. These findings suggest that impairments in LV systolic and diastolic function largely explain the association between impaired LA function and worse outcomes in HFpEF.
LA function by strain analysis using speckle tracking is a direct measurement of intrinsic LA myocardial deformation. Although not load independent, LA strain seems to be less dependent on loading conditions and geometric assumptions than traditional parameters 23, 24 and has high feasibility and reproducibility. 17 However, this measure still lacks clear standardization and validation. The presence of LA dysfunction by speckle tracking in HFpEF has been demonstrated in relatively small populations, and the reported prevalence of LA reservoir dysfunction was around 30%. [9] [10] [11] We found a high prevalence of LA reservoir dysfunction, independent of LA dilation. Patients with worse LA strain were older and the association between lower LA strain and older age may be related to the age-related loss or hypertrophy of myocytes, interstitial fibrosis, and impaired cellular calcium uptake that occurs in the LV 25, 26 and may affect the LA in parallel. 27 Indeed, we found that lower LA strain was related to more LVH and greater impairment of LV systolic and diastolic function. This association may, therefore, be because of shared risk factors impairing LV and LA function in parallel. Alternatively, or concomitantly, primary impairments in LV performance may result in abnormal LA performance. Worse LV longitudinal systolic function may contribute to LA dysfunction because of the influence of downward motion of the mitral plane during ventricular systole, leading to reduced systolic expansion of the LA. 28 Indeed, LA strain was highly correlated with LV longitudinal strain in our population (Figure 3 ). In addition, diastolic dysfunction with resulting elevation in LV filling pressure may contribute to LA dysfunction through increasing LA afterload and wall tension. [29] [30] [31] We noted significant associations of worse LA strain with higher E/E′ ratio and E/A ratio and lower E′. However, we cannot exclude the possibility that a primary abnormality of LA function, with reduced LA compliance, may result in a higher LA pressure for any given LV diastolic pressure, with resulting higher E-wave velocity and E/E′ ratio. The low prevalence of significative mitral regurgitation (12%) in our population may indicate that mitral valvular disease is not an major factor responsible for LA dysfunction in patients with HFpEF included in this analysis.
LA reservoir dysfunction is a predictor of cardiovascular outcomes in population-based studies, 32, 33 in patients with HF with reduced ejection fraction 34 and in patients with stable coronary heart disease and preserved ejection fraction. 35 Two studies have demonstrated the prognostic value of LA strain after acute myocardial infarction, but the larger of these studies (n=843 patients) showed that this association was not independent of GLS and LA size. 36, 37 There is little data on the prognostic relevance of LA dysfunction in HFpEF. A recent study of 101 highly symptomatic patients with HFpEF who were followed for a median of 350 days (31 events) demonstrated an association between reduced LA reservoir function (measuring by volumes) and increased risk of death after adjusting for age Hazard ratios (HRs) are per unit reduction in peak left atrial strain. ACA indicates aborted cardiac arrest; GLS, global longitudinal strain; HF, heart failure; and LVMi, left ventricular mass index. *Model 1: age, sex, race, randomization strata, enrollment region (Americas versus Russia/Georgia), randomized treatment assignment, history of atrial fibrillation, heart rate, New York Heart Association class, history of stroke, creatinine, hematocrit, left ventricular ejection fraction, left atrial volume index. and sex. A similar trend was also seen for LA active function (P=0.05). 12 In our study, we found that peak LA strain is associated with a risk of the composite end point and of HF hospitalization, but not cardiovascular mortality, after adjusting for clinical variables, LA size, LVEF, and LV mass. HF hospitalization may be more sensitive to changes in LA strain than cardiovascular mortality. Impaired LA function may contribute to clinical symptoms and decompensation in HFpEF through elevated pulmonary venous pressure and associated right heart dysfunction. 12 Indeed, we observed a significant association of impaired LA strain with LV filling pressure (E/E′ ratio), pulmonary pressure (tricuspid regurgitation velocity), and RV systolic function (RVFAC). In contrast to a recent study by Melenovsky et al, 12 we did not find LA dysfunction to be a predictor of mortality in HFpEF. This discrepancy may be because of differences in severity of illness of the study populations, with HFpEF patients in our study at a less advanced stage of the syndrome (56% patients New York Heart Association II) than the previous studied group (74% patients New York Heart Association III and IV). Importantly, peak LA strain no longer predicted adverse events after adjusting for LV GLS or LV filling pressure. Given the coupling of LA strain with LV longitudinal function because of the downward motion of the mitral plane in systole, and with LV filling pressure because of impact on LA wall tension, this finding suggests that LV systolic and diastolic dysfunction largely explain the association of LA dysfunction with adverse events in HFpEF. Atrial fibrillation is common in HFpEF and is associated with adverse outcomes. 38 Atrial fibrillation is also associated with worse LA function. 39 Importantly, however, LA strain was prognostic among patients in sinus rhythm, suggesting that impaired LA strain is not simply a marker of risk associated with atrial fibrillation. In contrast, we did not observe the same prognostic value of LA function in patients with normal LA size. We is adjusted for age, sex, race, enrollment region (Americas versus Russia/Georgia), randomization strata, history of atrial fibrillation, heart rate, New York Heart Association class, history of stroke, creatinine, hematocrit, left ventricular ejection fraction, LA volume index, and randomized treatment assignment. Hazard ratios are standardized and expressed per SD of the predictor variable. LA Dysfunction and HFpEF are unable to conclusively determine whether this is a consequence of the lower prevalence of LA dysfunction in patients with normal LA size compared with the overall population or if impaired LA function is a weaker predictor among patients with less advanced disease.
We observed an association of worse LA pump function with heightened risk of the composite end point and of HF alone. The prognostic importance of LA pump function in HFpEF is not well known. LA pump function is associated with risk of atrial fibrillation in patients with aortic stenosis 40 and in the general population, 41 but has also been associated with adverse cardiovascular events in hypertensive populations. 42, 43 Impaired LA contractile reserve secondary to progressive elevation of LV filling pressure may contribute to HFpEF symptoms, particularly during exercise. 44 Concomitantly, reduced LV longitudinal function, with associated impairment in LA systolic expansion and reservoir function, may result in increased reliance on late-diastolic LA pump function for adequate LV filling.
Several limitations of this analysis should be noted. We analyzed only a subset of the patients enrolled in the overall TOPCAT trial, with some notable differences between the patients included and excluded from this analysis. The generalizability of these findings to the overall TOPCAT population, and to the HFpEF syndrome more broadly, may therefore be limited. Significant differences in patient characteristics, event rates, and treatment response have been noted by region of enrollment (Americas versus Russia/ Georgia) in TOPCAT. 22 However, we found similar findings in a sensitivity analysis restricted to the patients enrolled in the Americas (Tables V and VI in the Data Supplement) . Although the analysis of 3D images may be a more accurate measurement of LA function, such images were not acquired in the TOPCAT trial. 45 Limited data are available on the stability of LA strain measures over time. In a subset of patients in this study, echocardiography was performed ≤6 months before randomization, possibly resulting in misclassification. In addition, the generalizability of these findings to patients with HFpEF in the community may be limited because of the inclusion and exclusion criteria of the TOPCAT trial.
In summary, LA dysfunction is associated with a higher risk of HF hospitalization in HFpEF, independent of potential clinical confounders, but not independent of LV systolic deformation and diastolic filling pressure. Concomitant impairments in LV systolic and diastolic function largely explain the association of LA dysfunction with adverse clinical outcomes in HFpEF. Our data suggested that the assessment of LA function does not have additional clinical use beyond the assessment of LV function in the prognostic evaluation of patients with HFpEF. Future studies are indicated to investigate the mechanisms responsible for coupled LA and LV dysfunction in HFpEF.
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